Logo

Innovent and AnHeart Report Interim Results of Taletrectinib (AB-106) in P-II TRUST Trial for the Treatment of ROS1-Positive NSCLC at CSCO 2021

Share this

Innovent and AnHeart Report Interim Results of Taletrectinib (AB-106) in P-II TRUST Trial for the Treatment of ROS1-Positive NSCLC at CSCO 2021

Shots:

  • The P-II TRUST trial evaluates taletrectinib (AB-106- ROS1/NTRK inhibitor) in 37 TKI-naïve or pre-treated patients with ROS1-positive NSCLC
  • As of June 16- 2021 cut off data- the therapy demonstrated an ORR (90.5% & 43.8%) & DCR (90.5% & 75.0%) in treatment-naïve & pre-treated patient. ROS1 G2032R resistant mutations were observed in three pre-treated patients & experienced tumor regression- 2 patients reported PR & 1 patient achieved SD
  • Additionally- patients with assessable brain metastasis pre-enrollment demonstrated intracranial ORR (83.3%) as assessed by the investigator. The therapy was safe with well- tolerated AEs

| Ref: PR Newswire | Image: Innovent

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions